Dr. Delese Darko
The Food and Drugs Authority (FDA) has slammed recent media reports that it claims have grossly misrepresented the outcome of a High Court ruling involving Tobinco Pharmaceuticals Ltd. The regulatory body expressed deep concern over allegations that its current CEO, Dr. Delese Darko, was negligent, leading to the FDA’s legal setback.
In a strongly worded statement, the FDA clarified that the case in question dates back to actions taken in 2013 under the leadership of the former CEO, Dr. Stephen Opuni. The authority emphasized that despite these claims, the current FDA leadership has consistently mounted a vigorous defense in court.
“The lawsuit, which was filed against us in 2019, has been met with a thorough and determined response at every stage of the proceedings,” the FDA stated.
The controversy erupted after some media outlets suggested that Dr. Darko’s alleged negligence was the reason for the FDA’s loss in the case. However, the authority has firmly rejected this narrative, maintaining that it has acted with diligence and integrity throughout the legal process.
“While the FDA acknowledges the judgment delivered by the High Court, the Authority respectfully disagrees with the decision and plans to exercise its right to appeal,” the statement continued.
The FDA also reaffirmed its unwavering commitment to upholding the rule of law and ensuring that due process is followed until the case reaches its final resolution.
This latest development adds a new twist to the ongoing saga, with the FDA standing by its actions and vowing to fight the ruling in the courts. As the situation unfolds, all eyes will be on the next legal move by the country’s top drugs regulator.
About The Author
